수의용 백신 시장 예측(-2034년) : 동물 유형, 백신 유형별, 대상 질환, 투여 경로, 유통 채널, 최종사용자, 기술 플랫폼, 병원체 유형별 및 지역별 세계 분석

According to Stratistics MRC, the Global Veterinary Vaccines Market is accounted for $13.9 billion in 2026 and is expected to reach $25.4 billion by 2034 growing at a CAGR of 7.8% during the forecast period. Veterinary vaccines are biological preparations administered to animals to stimulate immune responses against specific pathogens, protecting against infectious diseases. These vaccines are administered through various routes including injectable, oral, intranasal, ocular, spray vaccination, and other routes, serving companion animals and livestock across multiple species. The market distributes vaccines through veterinary hospitals and clinics, veterinary pharmacies, retail pharmacies, e-commerce platforms, government and public health programs, livestock farms and cooperatives, and other channels. Growing livestock production, increasing pet ownership, rising awareness of zoonotic disease prevention, and government disease control programs are key drivers of market expansion across all regions.

Market Dynamics:

Driver:

Increasing livestock production and demand for animal protein

The rapid growth in global livestock production and rising demand for animal protein are primary drivers for the veterinary vaccines market. As populations grow and diets shift toward higher protein consumption, livestock production continues expanding, creating substantial demand for animal health products. Vaccines are essential for maintaining herd health, improving productivity, and ensuring food safety. Disease outbreaks can cause significant economic losses for farmers, driving vaccine adoption. Emerging markets are expanding livestock production, creating new opportunities. As the global livestock sector grows to meet food demand, demand for veterinary vaccines continues rising, sustaining strong market expansion.

Restraint:

High vaccine development costs and regulatory requirements

The significant investment required for veterinary vaccine development and complex regulatory approval processes represent a major restraint for the veterinary vaccines market. Vaccine research, development, and clinical trials require substantial financial resources and time. Regulatory approval processes vary across countries, creating compliance complexity and costs. Maintaining cold chain requirements for vaccine distribution adds operational costs. Vaccine production requires specialized facilities and quality control systems. These development and regulatory costs may limit product innovation and market entry, particularly for smaller manufacturers with constrained resources.

Opportunity:

Advancements in vaccine technology and novel platforms

Innovations in veterinary vaccine technology present significant opportunities for market expansion. Recombinant, DNA, and RNA vaccine platforms are enabling development of more effective and safer vaccines. Vector-based and subunit vaccines offer improved safety profiles. Thermostable vaccine formulations reduce cold chain requirements. Reverse vaccinology and genomic approaches are accelerating vaccine development. Multi-valent vaccines providing broader protection are gaining adoption. As vaccine technologies advance, new products with enhanced efficacy and safety capture growing market share, expanding the addressable market.

Threat:

Vaccine hesitancy and public perception concerns

Growing vaccine hesitancy and public perception concerns about vaccine safety pose significant threats to the veterinary vaccines market. Some livestock producers may be reluctant to adopt new vaccines due to cost, efficacy concerns, or misinformation. Anti-vaccine sentiment in society can affect animal vaccine adoption. Safety concerns regarding vaccine adjuvants and preservatives persist. Alternative approaches including improved biosecurity and management may be preferred. Communication gaps about vaccine benefits can limit adoption. These perception challenges may slow growth in some regions and market segments.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the veterinary vaccines market. Initial disruptions included supply chain interruptions, reduced veterinary visits, and resource reallocation to human vaccine development. Vaccine production capacity constraints affected supply during the pandemic. However, the pandemic increased awareness of zoonotic diseases and preventive health, potentially benefiting vaccine adoption. Government support for vaccine production expanded. Pet ownership increased during lockdowns, creating new customers. Post-pandemic, heightened focus on disease prevention and vaccine awareness has sustained demand, with continued growth across livestock and companion animal segments.

The Injectable segment is expected to be the largest during the forecast period

The Injectable segment is expected to account for the largest market share during the forecast period, driven by its reliability, precise dosing, and superior immune response in most animal species. Injectable vaccines are administered through subcutaneous, intramuscular, or intradermal routes, enabling precise dosing and consistent immune response. The segment is widely used across all animal types and vaccine categories. Established application methods and existing veterinary infrastructure support continued use. The segment benefits from reliable immune responses and broad vaccine availability. With widespread adoption across all animal types and veterinary practices, injectable vaccines maintain the largest market share.

The E-commerce Platforms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the E-commerce Platforms segment is predicted to witness the highest growth rate, fueled by the growing adoption of online retail, convenience of direct-to-consumer delivery, and increasing comfort with purchasing pet and livestock products online. E-commerce platforms offer convenience, competitive pricing, and access to a broader product range. Expanding internet penetration and digital payment systems support market growth. Home delivery services appeal to pet owners and farmers with limited access to veterinary pharmacies. As online retail adoption continues growing across animal health, e-commerce delivers the fastest distribution channel growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by established veterinary healthcare infrastructure, high pet ownership, and strong livestock industry. The United States is a major market with comprehensive veterinary services. High pet healthcare spending and veterinary clinic access support market growth. Established veterinary vaccine manufacturers have significant presence. Strong regulatory framework ensures product quality and safety. With high pet ownership and livestock production, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly growing livestock production, increasing pet ownership, and expanding veterinary healthcare infrastructure across countries including China, India, and Southeast Asia. Rising incomes drive increased pet ownership and veterinary care spending. Growing livestock sectors create demand for disease prevention. Government animal health programs support vaccine adoption. Increasing awareness of veterinary healthcare benefits expands the addressable market. As veterinary healthcare infrastructure grows and adoption increases, Asia Pacific delivers the fastest veterinary vaccines market growth globally.

Key players in the market

Some of the key players in Veterinary Vaccines Market include Zoetis Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Ceva Sante Animale, Virbac S.A., HIPRA, Phibro Animal Health Corporation, Vetoquinol S.A., Biogenesis Bago S.A., Indian Immunologicals Limited, Hester Biosciences Limited, Dechra Pharmaceuticals PLC, Neogen Corporation, CZ Vaccines S.A.U., KM Biologics Co., Ltd., Agrovet Market S.A., and Biovac Ltd.

Key Developments:

In July 2026, Zoetis received European Commission marketing authorization for Poulvac(R) Procerta(R) HVT-ND, a live recombinant vector vaccine designed to protect chickens against Newcastle disease and Marek's disease with a single dose administered in ovo or at hatch.

In June 2026, Merck Animal Health announced the acquisition of TARGAN, Inc., a biotechnology company specializing in high-speed, automated targeted delivery systems for poultry and aquaculture vaccination.

In June 2026, Elanco announced the establishment of Elanco Ventures, backed by a $25 million multi-year commitment to fund early-stage startups working on next-generation veterinary therapeutics, vaccines, and One Health solutions.

In December 2025, Merck Animal Health received S&P Global's Best Product Companion Animal and Best Product Food Animal awards for its NUMELVI(TM) and INNOVAX(R) ND-IBD-ILT biological and therapeutic portfolios.

Animal Types Covered:

• Livestock Animals
• Companion Animals

Vaccine Types Covered:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• DNA Vaccines
• Vector-Based Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Other Vaccine Types

Disease Indications Covered:

• Foot-and-Mouth Disease (FMD)
• Rabies
• Newcastle Disease
• Avian Influenza
• Bovine Respiratory Disease (BRD)
• Porcine Circovirus Disease (PCV)
• Classical Swine Fever (CSF)
• Canine Distemper
• Canine Parvovirus
• Feline Leukemia Virus (FeLV)
• Infectious Bursal Disease (IBD)
• Marek's Disease
• Other Disease Indications

Routes of Administration Covered:

• Injectable
• Oral
• Intranasal
• Ocular
• Spray Vaccination
• Other Routes of Administration

Distribution Channels Covered:

• Veterinary Hospitals and Clinics
• Veterinary Pharmacies
• Retail Pharmacies
• E-commerce Platforms
• Government and Public Health Programs
• Livestock Farms and Cooperatives
• Other Distribution Channels

End Users Covered:

• Veterinary Hospitals
• Veterinary Clinics
• Livestock Farms
• Poultry Farms
• Swine Farms
• Aquaculture Farms
• Animal Shelters and Rescue Organizations
• Research Institutes and Universities
• Other End Users

Technology Platforms Covered:

• Conventional Vaccine Technology
• Recombinant Technology
• Genetic Engineering Technology
• Cell Culture-Based Technology
• mRNA Vaccine Technology
• Nanotechnology-Based Vaccines
• Other Technology Platforms

Pathogen Types Covered:

• Viral Vaccines
• Bacterial Vaccines
• Parasitic Vaccines
• Fungal Vaccines
• Combination Vaccines

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Vaccines Market, By Animal Type

• 5.1 Livestock Animals
  • 5.1.1 Cattle
  • 5.1.2 Poultry
  • 5.1.3 Swine
  • 5.1.4 Sheep and Goats
  • 5.1.5 Aquaculture Species
  • 5.1.6 Other Livestock Animals
• 5.2 Companion Animals
  • 5.2.1 Dogs
  • 5.2.2 Cats
  • 5.2.3 Horses
  • 5.2.4 Birds
  • 5.2.5 Other Companion Animals

6 Global Veterinary Vaccines Market, By Vaccine Type

• 6.1 Live Attenuated Vaccines
• 6.2 Inactivated Vaccines
• 6.3 Recombinant Vaccines
• 6.4 DNA Vaccines
• 6.5 Vector-Based Vaccines
• 6.6 Subunit Vaccines
• 6.7 Toxoid Vaccines
• 6.8 Conjugate Vaccines
• 6.9 Other Vaccine Types

7 Global Veterinary Vaccines Market, By Disease Indication

• 7.1 Foot-and-Mouth Disease (FMD)
• 7.2 Rabies
• 7.3 Newcastle Disease
• 7.4 Avian Influenza
• 7.5 Bovine Respiratory Disease (BRD)
• 7.6 Porcine Circovirus Disease (PCV)
• 7.7 Classical Swine Fever (CSF)
• 7.8 Canine Distemper
• 7.9 Canine Parvovirus
• 7.10 Feline Leukemia Virus (FeLV)
• 7.11 Infectious Bursal Disease (IBD)
• 7.12 Marek's Disease
• 7.13 Other Disease Indications

8 Global Veterinary Vaccines Market, By Route of Administration

• 8.1 Injectable
• 8.2 Oral
• 8.3 Intranasal
• 8.4 Ocular
• 8.5 Spray Vaccination
• 8.6 Other Routes of Administration

9 Global Veterinary Vaccines Market, By Distribution Channel

• 9.1 Veterinary Hospitals and Clinics
• 9.2 Veterinary Pharmacies
• 9.3 Retail Pharmacies
• 9.4 E-commerce Platforms
• 9.5 Government and Public Health Programs
• 9.6 Livestock Farms and Cooperatives
• 9.7 Other Distribution Channels

10 Global Veterinary Vaccines Market, By End User

• 10.1 Veterinary Hospitals
• 10.2 Veterinary Clinics
• 10.3 Livestock Farms
• 10.4 Poultry Farms
• 10.5 Swine Farms
• 10.6 Aquaculture Farms
• 10.7 Animal Shelters and Rescue Organizations
• 10.8 Research Institutes and Universities
• 10.9 Other End Users

11 Global Veterinary Vaccines Market, By Technology Platform

• 11.1 Conventional Vaccine Technology
• 11.2 Recombinant Technology
• 11.3 Genetic Engineering Technology
• 11.4 Cell Culture-Based Technology
• 11.5 mRNA Vaccine Technology
• 11.6 Nanotechnology-Based Vaccines
• 11.7 Other Technology Platforms

12 Global Veterinary Vaccines Market, By Pathogen Type

• 12.1 Viral Vaccines
• 12.2 Bacterial Vaccines
• 12.3 Parasitic Vaccines
• 12.4 Fungal Vaccines
• 12.5 Combination Vaccines

13 Global Veterinary Vaccines Market, By Geography

• 13.1 North America
  • 13.1.1 United States
  • 13.1.2 Canada
  • 13.1.3 Mexico
• 13.2 Europe
  • 13.2.1 United Kingdom
  • 13.2.2 Germany
  • 13.2.3 France
  • 13.2.4 Italy
  • 13.2.5 Spain
  • 13.2.6 Netherlands
  • 13.2.7 Belgium
  • 13.2.8 Sweden
  • 13.2.9 Switzerland
  • 13.2.10 Poland
  • 13.2.11 Rest of Europe
• 13.3 Asia Pacific
  • 13.3.1 China
  • 13.3.2 Japan
  • 13.3.3 India
  • 13.3.4 South Korea
  • 13.3.5 Australia
  • 13.3.6 Indonesia
  • 13.3.7 Thailand
  • 13.3.8 Malaysia
  • 13.3.9 Singapore
  • 13.3.10 Vietnam
  • 13.3.11 Rest of Asia Pacific
• 13.4 South America
  • 13.4.1 Brazil
  • 13.4.2 Argentina
  • 13.4.3 Colombia
  • 13.4.4 Chile
  • 13.4.5 Peru
  • 13.4.6 Rest of South America
• 13.5 Rest of the World (RoW)
  • 13.5.1 Middle East
    • 13.5.1.1 Saudi Arabia
    • 13.5.1.2 United Arab Emirates
    • 13.5.1.3 Qatar
    • 13.5.1.4 Israel
    • 13.5.1.5 Rest of Middle East
  • 13.5.2 Africa
    • 13.5.2.1 South Africa
    • 13.5.2.2 Egypt
    • 13.5.2.3 Morocco
    • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

• 14.1 Industry Value Network and Supply Chain Assessment
• 14.2 White-Space and Opportunity Mapping
• 14.3 Product Evolution and Market Life Cycle Analysis
• 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

• 15.1 Mergers and Acquisitions
• 15.2 Partnerships, Alliances, and Joint Ventures
• 15.3 New Product Launches and Regulatory Approvals
• 15.4 Capacity Expansion and Investments
• 15.5 Other Strategic Initiatives

16 Company Profiles

• 16.1 Zoetis Inc.
• 16.2 Merck Animal Health
• 16.3 Boehringer Ingelheim Animal Health
• 16.4 Elanco Animal Health Incorporated
• 16.5 Ceva Sante Animale
• 16.6 Virbac S.A.
• 16.7 HIPRA
• 16.8 Phibro Animal Health Corporation
• 16.9 Vetoquinol S.A.
• 16.10 Biogenesis Bago S.A.
• 16.11 Indian Immunologicals Limited
• 16.12 Hester Biosciences Limited
• 16.13 Dechra Pharmaceuticals PLC
• 16.14 Neogen Corporation
• 16.15 CZ Vaccines S.A.U.
• 16.16 KM Biologics Co., Ltd.
• 16.17 Agrovet Market S.A.
• 16.18 Biovac Ltd.